Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14491593 | 1.00 | SLC6A4 (0.44) | SLC6A4SLC6A3USP30KDM4EDRD2 | |
| SCHEMBL2861663 | 0.89 | KDM4E (0.49) | SLC6A4USP30KDM4EDRD2DRD3 | |
| SCHEMBL14491679 | 0.88 | USP30 (0.42) | SLC6A4USP30KDM4EDRD2DRD3 | |
| SCHEMBL2867705 | 0.85 | KDM4E (0.56) | SLC6A4SLC6A3USP30KDM4E | |
| SCHEMBL2469907 | 0.83 | KDM4E (0.44) | SLC6A4USP30KDM4EDRD2DRD3 | |
| SCHEMBL13066448 | 0.82 | KCNA3 (0.44) | SLC6A4SLC6A3USP30KDM4EDRD2 | |
| SCHEMBL13067017 | 0.80 | KDM4E (0.41) | SLC6A4SLC6A3USP30KDM4EDRD2 | |
| SCHEMBL13067024 | 0.80 | KCNA5 (0.60) | KCNA5 | |
| SCHEMBL5354274 | 0.80 | KCNA5 (0.60) | KCNA5 | |
| SCHEMBL13066980 | 0.80 | KCNA5 (0.60) | KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | SLC6A4 1950/4885SLC6A3 2504/4885USP30 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.